June 20, 2017

OncoSynergy and Infuseon Therapeutics Partner to Combat Glioblastoma

South San Francisco, California – June 20, 2017 – Infuseon Therapeutics and OncoSynergy have entered into a strategic alliance to test an investigational glioblastoma therapeutic, OS2966, in combination with a novel delivery device, the Cleveland Multiport CatheterTM. Glioblastoma is the most common and malignant primary brain tumor. Despite a median survival of merely 12 months, […]

May 9, 2016

OncoSynergy Appoints Oncology Drug Development Veteran Jean Pierre Bizzari, MD to Scientific Advisory Board

San Francisco, California – May 10, 2016 – OncoSynergy, Inc., a biopharma company developing a novel class of therapies for oncology, Resistance Mechanism Inhibitors (RMIs), announced today that it has appointed former Celgene and Sanofi-Aventis Executive, Jean Pierre Bizzari, MD, to its Scientific Advisory Board. Dr. Bizzari brings 33 years of industry experience with several […]

March 17, 2015

FDA Grants Second Orphan Designation for OS2966

San Francisco, California – (January 20, 2015) OncoSynergy announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for OS2966 in the treatment of ovarian cancer. The investigational drug candidate, a neutralizing anti-CD29 monoclonal antibody, received orphan designation for glioblastoma last summer. OS2966 is a first in class therapeutic […]

August 12, 2014

Orphan Drug Designation Obtained for OS2966

The FDA has granted orphan drug designation for our investigational monoclonal antibody OS2966 in the treatment of glioblastoma, the most common and malignant adult primary brain tumor. Link to press release: http://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-for-oncosynergys-investigational-monoclonal-antibody-os2966-in-the-treatment-of-glioblastoma-270887451.html

June 29, 2014

Emerging Company Profile in BioCentury, The Bernstein Report

OncoSynergy and our lead therapeutic program, OS2966, were featured in an ‘Emerging Company Profile’ in BioCentury, The Bernstein Report on BioBusiness. See pdf 061614_ECP_OncoSynergy The Bernstein Report is the flagship weekly publication of BioCentury Publications, Inc. providing analysis and commentary on the biopharma industry. OS2966 is currently under development for the treatment of orphan cancers with […]

January 10, 2014

OncoSynergy a Sponsor of 2014 Race for Hope (curebraintumors.org)

OncoSynergy is proud to be the Social Media Sponsor for the 17th running of the Race for Hope. This annual event to be held on May 4, 2014 in Washington, DC raises money and awareness for brain tumor research. In addition, the race will be run by Team OncoSynergy including our very own Dr. Shawn […]

December 17, 2013

OncoSynergy and CMC Biologics Enter into Agreement for OS2966 Drug Program

OncoSynergy and CMC Biologics enter into agreement to develop and manufacture material for IND enabling studies and phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody drug platform based on its “Targeted Synergy” approach — a transformative strategy allowing single drug inhibition of multiple fundamental cancer growth and treatment resistance mechanisms. OS2966 […]

November 22, 2013

Translational Research Award at World Federation of Neuro-Oncology Meeting

OncoSynergy collaborator, Manish K. Aghi, MD, PhD, Associate Professor of Neurosurgery at University of California at San Francisco, was awarded the Young Investigator Award for Basic/Translational Research at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology for work further describing a novel mechanism of antiangiogenic treatment resistance in glioblastoma. This builds upon initial […]

October 30, 2013

OncoSynergy highlighted in Startup Portraits

OncoSynergy highlighted in Startup Portraits feature of services provider, Science Exchange. Science Exchange is an online marketplace for outsourcing science experiments. OncoSynergy uses this platform extensively to dramatically increase our research capabilities. https://medium.com/startup-portraits/f08094280626

October 9, 2013

Martin Karplus awarded the 2013 Nobel Prize in chemistry

Martin Karplus, a co-inventor of key OncoSynergy technologies, awarded the 2013 Nobel Prize in chemistry. Professor Karplus is the Theodore William Richards Professor of Chemistry Emeritus at Harvard and Visiting Professor at the University of Strasbourg’s Institute of Science and Supramolecular Engineering (CNRS/ Université de Strasbourg). http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2013/press.html